PLK1 and non-small cell lung carcinoma: Furthermore, the combined inhibition of PLK1 and PI3K/AKT, along with FOXO1, exerts synergistic anticancer effects in anaplastic thyroid cancer and non-small cell lung cancer (37, 38).